Table 2. Overview of ongoing trials using SBRT and/or surgery as treatment for oligometastatic disease.

Clinical trial	Phase	Intervention	Control	Estimated enrollment	Primary endpoint
NCT03955198	II	SBRT + durvalumab	–	50	PFS
NCT02975609	II	CT + SBRT	CT + conventional RT	100	PFS
NCT04908956	II	Osimertinib + SBRT	Osimertinib	60	Safety + efficacy
NCT03965468	II	Durvalumab + CT + RT + surgery	–	47	PFS
NCT03275597	I	Durvalumab + tremelimumab + SBRT	–	31	Safety + tolerability
NCT02417662	III	SACT + conventional RT (primary tumor) + SBRT	SACT	340	OS
NCT04306926	II	TQB2450 (anti-PD-L1) + SBRT	–	59	PFS
NCT04758481	I/II	RT (primary tumor) + SBRT + maintenance RT	–	20	Toxicity + PFS
NCT04486287	II	Sintilimab + SBRT	–	44	ORR
NCT04255836	II	Durvalumab + CT + SBRT	–	35	PFS
NCT03827577	III	Surgery + SBRT + SACT	SACT	195	OS
NCT01725165	II	Surgery/RT + SOC	SOC	94	PFS
NCT03705403	II	SBRT/RT + immunocytokine L19-IL2	SOC	126	PFS
NCT04767009	II	SBRT + anti-PD-1	–	59	AEs + LFS

SBRT, stereotactic body radiation therapy; PFS, progression-free survival; CT, chemotherapy; RT, radiation therapy; SACT, systemic anticancer therapy; OS, overall survival; ORR, objective response rate; SOC, standard of care; AEs, adverse events; LFS, lesion-free survival.